AI Article Synopsis
- Cyclosporine A (CsA) is a popular immunosuppressant, but its connection to thrombotic microangiopathy (TMA) is uncommon and not often reported.
- A case study highlights a 34-year-old pregnant woman who developed TMA symptoms while taking CsA, but her condition improved after stopping the medication.
- This study is the first to document CsA-induced TMA in pregnancy, and it reviews previous cases to outline mechanisms, characteristics, risk factors, and detection methods for this rare side effect.
Article Abstract
Cyclosporine A (CsA) is a commonly used immunosuppressant, but its association with thrombotic microangiopathy (TMA) is rarely reported. In recent years, CsA has been used in pregnant women with autoimmune diseases or previous immune-related adverse pregnancies. Our case involves a 34-year-old female who developed typical laboratory indicators of TMA while using CsA to improve pregnancy outcomes. After discontinuing CsA, the TMA markers gradually normalized. To our knowledge, this is the first report of CsA-induced TMA during pregnancy. We also reviewed previous case reports of CsA-induced TMA and summarized the possible mechanisms, characteristics, and risk factors, as well as methods to identify this rare adverse effect of CsA in pregnant women.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700391 | PMC |
| http://dx.doi.org/10.1177/2050313X241308693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!